### **spirit**health

# Insupen pen needles review service in the South of England

An ICB in the South of England is set to launch an Insupen pen needle implementation with Spirit Health's end-to-end Active Implementation<sup>™</sup> service. This will result in patients using quality Insupen pen needles including the thinnest<sup>1</sup> and most cost-effective needle on the Drug Tariff<sub>2</sub>.

Spirit Health can help improve patient outcomes whilst ensuring the patient receives quality products. Additionally, prescribing Insupen will result in saving the ICB money which they can allocate to other areas.

## Projected savings p/a\*

#### £125,631 - £162,696

Annual savings shown are correct as of GPRX data Oct-2022-Sep-2023, based on a realistic 70% switch rate.

Current pen needle spend

£382,104\*

#### **Aims & Objectives**

1. 33g finest needle on NHS BSA Drug Tariff, Dec 2022 2. Insupen Original Drug Tariff pricing from Dec 2022, can be accessed Drug Tariff | NHSBSA

To **educate patients** on appropriate use of pen needles as part of their diabetes management

Reduce expenditure on pen needles by switching **75% of pen needles patients** and **deliver projected savings £125,631 - £162,696** per annum

Improve quality of patient care

#### **Expected outcomes**

$\left( \right)$	$\rangle$
$\checkmark$	

ΰn

**Reduced pen needle expenditure** Medicines optimisation teams will see a reduction in pen needle product spend.



Maintain and uphold patient care Supported patients will be able to safely and confidently use pen needles.



All prescription changes aligned to the formulary guidelines Formularies help control costs and ensures patients receive consistent care.



#### How it works



#### Identify patients

The Spirit Clincal Team carries out an audit on GP Practice clinical system to identify patients suitable for review. Patients will be changed to the same length and gauge needle.



#### **Communication to patients**

The Spirit Clincial Team will send letters to the agreed patients to inform them of the pen needle change.



The GP will review and approve the patient list. This will be a direct and remote pen needle switch.



Remote pen needle update

The Spirit team will action the product update on the clinical system – this is completed remotely.



#### Final review and evaluation

The Spirit Clinical Team will review the work undertaken with the GP against the objectives set once implementation is complete.

> Click here to learn more about our medicines optimisation solutions

HEA5008DEC23

3



Spirit Family of Companies Spirit House, Saffron Way Leicester, LE2 6UP T: 0116 286 5000 www.spirit-health.com meds-op@spirit-health.com